Evoke Pharma, Inc.
420 Stevens Avenue, Suite 370
Solana Beach, CA 92075
December 26, 2017
VIA EDGAR
Ms. Dorrie Yale
Division of Corporation Finance
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
| Re: | Evoke Pharma, Inc. Registration Statement on Form S-3 Filed November 14, 2017 File No. 333-221556 |
Dear Ms. Yale:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf Evoke Pharma, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on Thursday, December 28, 2017, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Cheston J. Larson, Esq. of Latham & Watkins LLP at (858) 523-5435. Thank you for your assistance and cooperation in this matter.
| Very truly yours,
EVOKE PHARMA, INC. | ||
| By: | /s/ Matthew J. D’Onofrio | |
| Matthew J. D’Onofrio Executive Vice President, Chief Business Officer and Secretary | ||
| cc: | Cheston J. Larson, Esq., Latham & Watkins LLP Matthew T. Bush, Esq., Latham & Watkins LLP |